【5 月 12 日,高盛报告称百济神州在慢性淋巴细胞白血病领域地位有望巩固】高盛指出,百济神州的 BTK/BCL2 产品组合在该领域潜力巨大,其中 BCL2 抑制剂或颠覆一线 CLL 治疗模式,BTK 降解剂初步反应数据良好且耐受性佳。 基于此,高盛对百济神州美国预托证券及 A 股目标价分别上调至 352.98 美元及 295.09 元,投资评级为“买入”。 高盛还预测,该药物组合 2035 年经...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.